The aim of this study is to support the efficacy of Permixon 160 mg b.i.d. in treating subjects with symptomatic Benign Prostatic Hyperplasia (BPH), compared to placebo, using Tamsulosine LP 0.4 mg as a reference treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
833
Oral administration - 160 mg twice daily.
Oral administration - 0.4 mg daily.
Oral administration - twice daily.
International Prostate Symptom Score (I-PSS score) change
I-PSS score change from baseline to D180
Time frame: Day 180
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Oral administration - daily.
Unnamed facility
Benešov, Czechia
Unnamed facility
Litoměřice, Czechia
Unnamed facility
Pilsen, Czechia
Unnamed facility
Prague, Czechia
Unnamed facility
Roudnice nad Labem, Czechia
Unnamed facility
Sternberk, Czechia
Unnamed facility
Ústí nad Labem, Czechia
Unnamed facility
Angers, France
Unnamed facility
Créteil, France
Unnamed facility
Limoges, France
...and 48 more locations